2023 Pain Management Symposium Enduring Material
This enduring material has been approved by KBML as meeting the statutory requirements of HB1 and the Consolidated Appropriations Act (MATE)
Learn now and fulfill your state-mandated Continuing Medical Education (CME) credits.
This activity has been approved by:
Kentucky Medical Association for a maximum of 8 AMA PRA Category 1 Credits™
Kentucky Board of Medical Licensure for a maximum of 8 AMA PRA Category 1 Credits™ – meeting the mandatory CME requirements for HB1/MATE Act/Prescribing Controlled Substances
Kentucky Board of Nursing for up to 8 CEUs
Kentucky Board of Respiratory Care for up to 8 CEU hours
Kentucky Board of Pharmacy for up to 8 CEU hours
Kentucky Board of Imaging & Radiation Therapy for up to 8 CEU hours
Kentucky Physical Therapy Association for up to 8 contact hours
Release Date: October 16, 2023
Expiration Date: October 16, 2026
(Please note that credit will no longer be issued for this activity after this date)
Media Type: Internet Enduring Material Activity / Live Lecture Video
Completion Time: 8.00 hours
Registration Fee: FREE
Target Audience:
This symposium is designed to meet the educational needs of physicians, physician assistants, nurse practitioners, family practitioners, medical students, nurses, and all other allied health professionals caring for pain management patients.
Speakers:
- Danesh Mazloomdoost, MD
- Martika Martin, PharmD, MBA, BCGP, RPh
- Dana Quesinberry, JD, DrPH
- Alexander Bautista, MD, MBA, FASA
- Eloise Fields, DO
- Chris Delcher, PhD
- Michael E. Harned, MD
Learning Objectives:
At the completion of this program, the participant will be able to:
- Discuss the pathophysiology of chronic pain and impact of opioids
- Define the joint degenerative process
- Identify the framework to treat pain sustainably without opioids
- Summarize the neuropath physiology of pain and addiction
- Summarize the pharmacology of buprenorphine
- Identify formulations of buprenorphine
- Examine the role of buprenorphine in the treatment of opioid use disorder
- Discuss FDA approved dosing of buprenorphine for opioid use disorder
- Explain micro-induction of buprenorphine & its place in therapy for treatment of opioid use disorder
- Describe federal and state regulations related to the prescribing of buprenorphine
- Define the role of fentanyl and analogs in fatal and nonfatal overdoses in Kentucky
- Assess the value of public health surveillance of drug overdose to tertiary care decision making
- Integrate surveillance data into current clinical decision-making support tools
- Differentiate drug involvement in overdoses by geography, biological sex, race/ethnicity, and age
- Assess the impact of the opioid cases
- Describe the importance of patient assessment before initiating opioid therapy
- Discuss alternative treatment options
- Utilize guidance on initiating opioid therapy
- Review the importance of ongoing monitoring and follow-up
- Examine the 3 FDA approved medications for opioid use disorder
- Review basic concepts surrounding treatment of withdrawal and pain in patients with opioid use disorder and how they relate
- Develop strategies for managing pain in patients with OUD and recognize how MOUD alters pain management
- Review all relevant updates to KASPER that may affect clinical practice
- Explain the role of KASPER and PDMPs in population-based research on controlled substances
- Identify trends in epidemiology and licit and illicit drug use in Kentucky and beyond
- Explain what interventional pain medicine can now offer in patients with spinal pain
- Recognize when to refer patients for advanced pain procedures
- Describe pharmacological properties, mechanism of action & indications for use in opioid use disorder
- Discuss preoperative assessment & management of buprenorphine and methadone during preoperative period
- Discuss strategies and existing guidelines and recommendations and the importance of multidisciplinary collaboration in patients on buprenorphine and methadone for OUD
Instructions for Participation and Credit:
To receive credit you are required to:
- Review video content,
- Complete the activity quiz
- Submit the CME/CE registration and evaluation.
After completion of the activity, a certificate will be sent to you via your preferred retrieval method as listed on the evaluation. If you have questions about the participation process, please e-mail CME@pikevillehospital.org or call (606) 430-8110
Accreditation & Designation Statement
Physicians
Accreditation: Pikeville Medical Center is accredited by the Kentucky Medical Association to provide continuing medical education for physicians.
Designation: Pikeville Medical Center designates this internet enduring material for a maximum of 8.0 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in the activity.
Disclaimer
The opinions and recommendations expressed by faculty and other experts, whose input is included in this activity, are their own and do not represent Pikeville Medical Center endorsement. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacological therapy to patients.
Special Needs Statement
If you have special needs, please contact our office and we will do our best to accommodate you.
Disclosure of Relevant Financial Relationships
It is the policy of Pikeville Medical Center to adhere to ACCME Criteria, Policies, and Standards for Integrity and Independence in Accredited Continuing Education in order to ensure fair balance, independence, objectivity, and scientific rigor in all its accredited activities. All faculty and planners, along with the Activity Director and Co-Director, participating in accredited activities are expected to disclose relevant financial relationships pertaining to their contribution to the activity. Relationship information is analyzed to determine whether conflicts of interest exist. All conflicts of interest are mitigated prior to participation in the planning or implementation of this activity.
Faculty members are also expected to disclose any discussion of (1) off label or investigational uses of FDA approved commercial products or devices or (2) products or devices not yet approved in the United States. All disclosures will be made at the time of this accredited continuing education activity.
The following Course Faculty and Planning Committee have reported having no relevant financial relationships with any ineligible company related to the content of this educational activity.
Course Faculty:
John Blackburn, MD
Danesh Mazloomdoost, MD
Martika Martin, PharmD, MBA, BCGP, RPh
Dana Quesinberry, JD, DrPH
Alexander Bautista, MD, MBA, FASA
Eloise Fields, DO
Michael E. Harned, MD
Planning Committee:
Brenda Adams, CCMEC, Director Continuing Medical Educatiom
Melissa Bowles, Medical Education Coordinator
Michelle Caudill, BSN, RN, Staff Development Specialist
